This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
LRRK2 Program (Denali/Genentech)
Denali Therapeutics Inc.
Drug Names(s): LRRK2 Parkinson's Program
Description: Denali and Genentech are developing LRRK2 inhibitors for the treatment of Parkinson's disease.
Denali and Genentech
In August 2016, Denali disclosed a licensing agreement with Genentech, a member of the Roche group, for exclusive global rights to develop and commercialize LRRK2 inhibitors for the treatment of Parkinson's disease.
Partners: Roche Holding AG
LRRK2 Program (Denali/Genentech) News
Additional information available to subscribers only: